Caryn Parlavecchio, Chief Human Resources Officer at Scholar Rock Holding Corp (NASDAQ: SRRK), executed a sale of 6,600 shares of the company's common stock on January 16, 2026. The shares were sold at a price of approximately $44.48 per share, resulting in proceeds totaling $293,552.
This transaction was formally reported through a Form 4 filing with the Securities and Exchange Commission (SEC). The sale arose from a need to cover tax withholding obligations following the vesting of restricted stock units (RSUs) on January 15, 2026. According to the filing’s footnotes, this sale was performed pursuant to Scholar Rock’s equity incentive plans and was not a discretionary trade made by Parlavecchio personally.
After completing this transaction, Parlavecchio directly holds 148,864 shares in total, which includes 78,283 shares of common stock and an additional 70,581 RSUs.
Meanwhile, Scholar Rock has recently drawn attention from industry analysts and investors, due in part to its focus on rare-disease biotechnology. UBS has initiated coverage with a Buy rating and a $60 price target, emphasizing the company’s potential, especially concerning its primary candidate, apitegromab. Similarly, Cantor Fitzgerald reiterates an Overweight rating, expressing confidence in the approval outlook for apitegromab, which is developed for spinal muscular atrophy (SMA).
In regulatory updates, Scholar Rock disclosed that its manufacturing partner, Catalent Indiana, received a warning letter from the U.S. Food and Drug Administration (FDA). Despite this, the company intends to resubmit its biologics license application for apitegromab and targets a U.S. launch within 2026, contingent upon regulatory clearance.
Further reflecting market sentiment, Wolfe Research has initiated coverage with an Outperform rating and a price target of $42, notwithstanding the FDA's recent Complete Response Letter for apitegromab. BMO Capital Markets also upgraded its price target for Scholar Rock to $50 from $45 and maintained an Outperform stance, noting the company’s acceleration of technology transfer to an additional manufacturing facility.
These analyst reports highlight ongoing optimism regarding Scholar Rock’s strategic initiatives and robust drug development trajectory within the biotech sector, contributing to active investor interest and market discourse.